Company / Shareholders' Equity
Aurinia Pharmaceuticals Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$581.3M
FY2025
5-year range
$298.6M / $581.3M
FY2021-FY2025
Trend
+54.0%
vs FY2024
Sector context
#85 of 213
Health Care
What the data says
At $581M, Aurinia Pharmaceuticals Inc.'s shareholders' equity ranks #85 of 213 in the Health Care sector. Shareholders' Equity returned to growth in FY2025 after 2 years of decline, reaching $581M.
Based on SEC 10-K filings.
$581M in FY2025 with a 5-year CAGR of +7.4%.
Improved from $378M to $581M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +12.5%
- 5-Year CAGR
- +7.4%
- 10-Year CAGR
- -
Sector benchmark
#85 of 213 in Health CareTop 40% of 213This company $581.3M Sector average $2.5B
▼
-77.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.4%, indicating consistent growth.
- In FY2025, shareholders' equity increased 54.0% year-over-year.
- Ranks #85 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $581.3M | +54.0% |
| FY2024 | $377.5M | -0.1% |
| FY2023 | $378.0M | -7.3% |
| FY2022 | $407.8M | +36.6% |
| FY2021 | $298.6M | -26.8% |
| FY2020 | $407.8M | +36.6% |
| FY2019 | $298.6M | +120.0% |
| FY2018 | $135.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026